JP2024023667A - Liver function improver - Google Patents
Liver function improver Download PDFInfo
- Publication number
- JP2024023667A JP2024023667A JP2023210781A JP2023210781A JP2024023667A JP 2024023667 A JP2024023667 A JP 2024023667A JP 2023210781 A JP2023210781 A JP 2023210781A JP 2023210781 A JP2023210781 A JP 2023210781A JP 2024023667 A JP2024023667 A JP 2024023667A
- Authority
- JP
- Japan
- Prior art keywords
- mass
- parts
- liver function
- tectorigenins
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003908 liver function Effects 0.000 title abstract description 73
- OBBCRPUNCUPUOS-UHFFFAOYSA-N tectorigenin Chemical compound O=C1C2=C(O)C(OC)=C(O)C=C2OC=C1C1=CC=C(O)C=C1 OBBCRPUNCUPUOS-UHFFFAOYSA-N 0.000 claims abstract description 26
- UYLQOGTYNFVQQX-UHFFFAOYSA-N psi-tectorigenin Natural products COC1=C(O)C=C(O)C(C2=O)=C1OC=C2C1=CC=C(O)C=C1 UYLQOGTYNFVQQX-UHFFFAOYSA-N 0.000 claims abstract description 13
- OYUJPVCKGSEYDD-UHFFFAOYSA-N tectorigenin Natural products COc1c(O)cc2OCC(C(=O)c2c1O)c1ccc(O)cc1 OYUJPVCKGSEYDD-UHFFFAOYSA-N 0.000 claims abstract description 13
- 240000007594 Oryza sativa Species 0.000 claims description 20
- 235000007164 Oryza sativa Nutrition 0.000 claims description 20
- 239000000843 powder Substances 0.000 claims description 20
- 235000009566 rice Nutrition 0.000 claims description 20
- 239000000463 material Substances 0.000 claims description 19
- 239000000284 extract Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000000855 fermentation Methods 0.000 claims description 11
- 230000004151 fermentation Effects 0.000 claims description 11
- 239000000052 vinegar Substances 0.000 claims description 11
- 235000021419 vinegar Nutrition 0.000 claims description 11
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 8
- 235000003261 Artemisia vulgaris Nutrition 0.000 claims description 7
- 240000006891 Artemisia vulgaris Species 0.000 claims description 7
- 235000013339 cereals Nutrition 0.000 claims description 7
- 235000003599 food sweetener Nutrition 0.000 claims description 7
- 239000003765 sweetening agent Substances 0.000 claims description 7
- MCYJIRFKDCXYCX-YUPZTAPUSA-N COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O Chemical compound COc1c(O[C@@H]2O[C@H](CO[C@@H]3OC[C@@H](O)[C@H](O)[C@H]3O)[C@@H](O)[C@H](O)[C@H]2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-YUPZTAPUSA-N 0.000 claims description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 6
- 239000013538 functional additive Substances 0.000 claims description 6
- MCYJIRFKDCXYCX-UHFFFAOYSA-N tectorigenin 7-O-xylosylglucoside Natural products COc1c(OC2OC(COC3OCC(O)C(O)C3O)C(O)C(O)C2O)cc2occ(-c3ccc(O)cc3)c(=O)c2c1O MCYJIRFKDCXYCX-UHFFFAOYSA-N 0.000 claims description 6
- -1 tectorizin Chemical compound 0.000 claims description 5
- 235000015099 wheat brans Nutrition 0.000 claims description 5
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 4
- 108010011485 Aspartame Proteins 0.000 claims description 4
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 4
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 4
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 4
- 239000000605 aspartame Substances 0.000 claims description 4
- 235000010357 aspartame Nutrition 0.000 claims description 4
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 4
- 229960003438 aspartame Drugs 0.000 claims description 4
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 4
- 229940074393 chlorogenic acid Drugs 0.000 claims description 4
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 4
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 4
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 4
- 235000012754 curcumin Nutrition 0.000 claims description 4
- 229940109262 curcumin Drugs 0.000 claims description 4
- 239000004148 curcumin Substances 0.000 claims description 4
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 3
- 229960001948 caffeine Drugs 0.000 claims description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 3
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 229960002160 maltose Drugs 0.000 claims description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract description 8
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract description 6
- 229940088594 vitamin Drugs 0.000 abstract description 6
- 229930003231 vitamin Natural products 0.000 abstract description 6
- 235000013343 vitamin Nutrition 0.000 abstract description 6
- 239000011782 vitamin Substances 0.000 abstract description 6
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 abstract description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 abstract description 4
- 229930003471 Vitamin B2 Natural products 0.000 abstract description 4
- 229930003427 Vitamin E Natural products 0.000 abstract description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract description 4
- 230000006872 improvement Effects 0.000 abstract description 4
- 229960002477 riboflavin Drugs 0.000 abstract description 4
- GQTHJBOWLPZUOI-FJXQXJEOSA-M sodium D-pantothenate Chemical compound [Na+].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O GQTHJBOWLPZUOI-FJXQXJEOSA-M 0.000 abstract description 4
- 229940068459 sodium pantothenate Drugs 0.000 abstract description 4
- 235000019164 vitamin B2 Nutrition 0.000 abstract description 4
- 239000011716 vitamin B2 Substances 0.000 abstract description 4
- 235000019165 vitamin E Nutrition 0.000 abstract description 4
- 239000011709 vitamin E Substances 0.000 abstract description 4
- 229940046009 vitamin E Drugs 0.000 abstract description 4
- 235000020958 biotin Nutrition 0.000 abstract description 3
- 239000011616 biotin Substances 0.000 abstract description 3
- 229960002685 biotin Drugs 0.000 abstract description 3
- 150000003722 vitamin derivatives Chemical class 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 description 47
- 239000004615 ingredient Substances 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 23
- 235000013305 food Nutrition 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 241000196324 Embryophyta Species 0.000 description 19
- 240000006439 Aspergillus oryzae Species 0.000 description 17
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 17
- 239000000047 product Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000000605 extraction Methods 0.000 description 15
- 210000003494 hepatocyte Anatomy 0.000 description 15
- 230000004913 activation Effects 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000002360 preparation method Methods 0.000 description 12
- 238000009472 formulation Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 239000008187 granular material Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 239000002537 cosmetic Substances 0.000 description 8
- 239000002994 raw material Substances 0.000 description 8
- 230000002195 synergetic effect Effects 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 241000234314 Zingiber Species 0.000 description 7
- 235000006886 Zingiber officinale Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 235000008397 ginger Nutrition 0.000 description 7
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 244000062793 Sorghum vulgare Species 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 235000019713 millet Nutrition 0.000 description 5
- 241000228212 Aspergillus Species 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- AGBQKNBQESQNJD-SSDOTTSWSA-N (R)-lipoic acid Chemical compound OC(=O)CCCC[C@@H]1CCSS1 AGBQKNBQESQNJD-SSDOTTSWSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241001113425 Iridaceae Species 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- AGBQKNBQESQNJD-UHFFFAOYSA-N alpha-Lipoic acid Natural products OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 235000019437 butane-1,3-diol Nutrition 0.000 description 3
- 229910002091 carbon monoxide Inorganic materials 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 235000019136 lipoic acid Nutrition 0.000 description 3
- 229910052750 molybdenum Inorganic materials 0.000 description 3
- 239000011733 molybdenum Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000012488 sample solution Substances 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 229960002663 thioctic acid Drugs 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229910052719 titanium Inorganic materials 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 2
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 241000228251 Aspergillus phoenicis Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000220485 Fabaceae Species 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241000395050 Kaempferia parviflora Species 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 239000008278 cosmetic cream Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 229940074391 gallic acid Drugs 0.000 description 2
- 235000004515 gallic acid Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 231100000234 hepatic damage Toxicity 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000021374 legumes Nutrition 0.000 description 2
- 230000008818 liver damage Effects 0.000 description 2
- 229960003646 lysine Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 235000021395 porridge Nutrition 0.000 description 2
- 229960002429 proline Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000015067 sauces Nutrition 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- PJVXUVWGSCCGHT-ZPYZYFCMSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;(3s,4r,5r)-1,3,4,5,6-pentahydroxyhexan-2-one Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC[C@@H](O)[C@@H](O)[C@H](O)C(=O)CO PJVXUVWGSCCGHT-ZPYZYFCMSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical class CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- 101150032765 ARNTL gene Proteins 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000005714 Artemisia indica Nutrition 0.000 description 1
- 244000067509 Artemisia indica Species 0.000 description 1
- 241001513093 Aspergillus awamori Species 0.000 description 1
- 241000122821 Aspergillus kawachii Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001112078 Aspergillus usamii Species 0.000 description 1
- 101000856500 Bacillus subtilis subsp. natto Glutathione hydrolase proenzyme Proteins 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 240000006766 Cornus mas Species 0.000 description 1
- 235000003363 Cornus mas Nutrition 0.000 description 1
- 241000371652 Curvularia clavata Species 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- GZIFEOYASATJEH-UHFFFAOYSA-N D-delta tocopherol Natural products OC1=CC(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-UHFFFAOYSA-N 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 244000182691 Echinochloa frumentacea Species 0.000 description 1
- 235000008247 Echinochloa frumentacea Nutrition 0.000 description 1
- 240000008620 Fagopyrum esculentum Species 0.000 description 1
- 235000009419 Fagopyrum esculentum Nutrition 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 241001299819 Hordeum vulgare subsp. spontaneum Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 244000046146 Pueraria lobata Species 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 108050002485 Sirtuin Proteins 0.000 description 1
- 102000011990 Sirtuin Human genes 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000015173 baked goods and baking mixes Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 235000021438 curry Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000021121 fermented vegetables Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940002508 ginger extract Drugs 0.000 description 1
- 235000020708 ginger extract Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical compound [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- PDKHNCYLMVRIFV-UHFFFAOYSA-H molybdenum;hexachloride Chemical compound [Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Cl-].[Mo] PDKHNCYLMVRIFV-UHFFFAOYSA-H 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000003495 polar organic solvent Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 235000013570 smoothie Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 235000013547 stew Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- FHFSSMDJUNVMNY-UHFFFAOYSA-N tectoridin Natural products COc1c(O)c2C(=O)C(=COc2cc1OC3OC(CO)C(O)C(O)C3O)c4cccc(O)c4 FHFSSMDJUNVMNY-UHFFFAOYSA-N 0.000 description 1
- CNOURESJATUGPN-UDEBZQQRSA-N tectoridin Chemical compound C1=C2OC=C(C=3C=CC(O)=CC=3)C(=O)C2=C(O)C(OC)=C1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CNOURESJATUGPN-UDEBZQQRSA-N 0.000 description 1
- KWXLCDNSEHTOCB-UHFFFAOYSA-J tetrasodium;1,1-diphosphonatoethanol Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P(=O)([O-])C(O)(C)P([O-])([O-])=O KWXLCDNSEHTOCB-UHFFFAOYSA-J 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000005418 vegetable material Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000008256 whipped cream Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011670 zinc gluconate Substances 0.000 description 1
- 235000011478 zinc gluconate Nutrition 0.000 description 1
- 229960000306 zinc gluconate Drugs 0.000 description 1
- GZIFEOYASATJEH-VHFRWLAGSA-N δ-tocopherol Chemical compound OC1=CC(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 GZIFEOYASATJEH-VHFRWLAGSA-N 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
Description
本発明は、肝機能改善剤に係り、詳しくは、テクトリゲニン類及び特定の他成分を含有することを特徴とする肝機能改善剤に関する。 The present invention relates to a liver function improving agent, and more particularly to a liver function improving agent characterized by containing tectorigenins and specific other ingredients.
テクトリゲニン類はアヤメ科やマメ科の植物に存在するフラボノイドの一つであり、サーチュインを活性化すること（特許文献１参照）、Ｂｍａｌ１遺伝子の発現を活性化すること等が知られている（特許文献２参照）。
テクトリゲニン類は植物に含まれていることから、安全性が比較的高く日常的に摂取しやすいと考えられるが、その活性や機能については未だ不明な点も多い。
Tectorigenins are one of the flavonoids present in plants of the Iridaceae and Fabaceae families, and are known to activate sirtuins (see Patent Document 1) and Bmal1 gene expression (Patent Document 1). (See Reference 2).
Since tectorigenins are found in plants, they are considered to be relatively safe and easy to ingest on a daily basis, but there are still many unknowns about their activities and functions.
そこで、本発明においては、テクトリゲニン類と特定の他成分とを組み合わせて、従来にない優れた肝機能改善剤を得ることを目的に種々の検討を行った。 Therefore, in the present invention, various studies were conducted with the aim of obtaining an unprecedented and superior liver function improving agent by combining tectorigenins and specific other ingredients.
本発明者らは、テクトリゲニン類と多種多様な成分とを組み合わせて肝機能改善作用を試験したところ、テクトリゲニン類と特定の他成分とを組み合わせることにより、肝機能改善作用が飛躍的に向上することを見い出した。 The present inventors tested liver function improving effects by combining tectorigenins with a wide variety of ingredients, and found that the liver function improving effect was dramatically improved by combining tectorigenins with specific other ingredients. I found out.
本発明は具体的には、
テクトリゲニン類と、下記（ａ）～（ｆ）からなる群より選ばれる少なくとも１種の成分とを含有することを特徴とする肝機能改善剤である。
（ａ）ビタミンＢ２、パントテン酸ナトリウム、ビオチン、ビタミンＥから選ばれる少なくとも１種のビタミン類
（ｂ）ヨモギ、黒ショウガ（Ｋａｅｍｐｆｅｒｉａ ｐａｒｖｉｆｌｏｒａ）、米ぬか、米胚芽から選ばれる少なくとも１種の植物素材
（ｃ）穀物麹、黒酢、小麦ふすま発酵エキス末、もろみ酢、ビール酵母から選ばれる少なくとも１種の発酵関連素材
（ｄ）アラニン、イソロイシン、リジン、プロリン、チロシンから選ばれる少なくとも１種のアミノ酸（塩を含む）
（ｅ）鉄、モリブデン、亜鉛、チタン、没食子酸、クロロゲン酸、クルクミン、カフェイン、Ｌ－カルニチン、α‐リポ酸から選ばれる少なくとも１種の機能性添加剤
（ｆ）アスパルテーム、麦芽糖、フラクトオリゴ糖から選ばれる少なくとも１種の甘味料
Specifically, the present invention includes:
This is a liver function improving agent characterized by containing tectorigenins and at least one component selected from the group consisting of (a) to (f) below.
(a) At least one vitamin selected from vitamin B2, sodium pantothenate, biotin, and vitamin E (b) At least one plant material selected from mugwort, black ginger (Kaempferia parviflora), rice bran, and rice germ (c ) At least one fermentation-related material selected from grain koji, black vinegar, wheat bran fermented extract powder, moromi vinegar, and brewer's yeast (d) At least one amino acid (salt) selected from alanine, isoleucine, lysine, proline, and tyrosine including)
(e) At least one functional additive selected from iron, molybdenum, zinc, titanium, gallic acid, chlorogenic acid, curcumin, caffeine, L-carnitine, and α-lipoic acid (f) Aspartame, maltose, fructooligosaccharide At least one sweetener selected from
また、本発明は、テクトリゲニン類と（ａ）～（ｆ）からなる群より選ばれる少なくとも１種の成分とからなる成分を添加して得たことを特徴とする肝機能改善剤であることが好ましい。 The present invention also provides a liver function improving agent obtained by adding a component consisting of tectorigenins and at least one component selected from the group consisting of (a) to (f). preferable.
また、本発明は、錠剤、カプセル剤、粉末剤、顆粒剤、又は液剤であることを特徴とする肝機能改善剤であることが好ましい。 Furthermore, the present invention preferably provides a liver function improving agent characterized by being in the form of a tablet, capsule, powder, granule, or liquid.
本発明によれば、優れた肝機能改善作用を有する肝機能改善剤を提供することができる。 According to the present invention, a liver function improving agent having an excellent liver function improving effect can be provided.
本発明の肝機能改善剤としては、テクトリゲニン類及び特定の他成分を含有するものであれば特に制限されるものではない。また、本発明の肝機能改善剤は優れた肝機能改善作用を有し、肝機能の亢進又は肝障害の抑制が期待できる。特に、本発明のテクトリゲニン類と特定の他成分との組み合わせは、肝細胞の傷害を防ぐ。これにより、肝細胞中のアスパラギン酸アミノトランスフェラーゼ（ＡＳＴ）、アラニンアミノ基転移酵素（Ａｌａｎｉｎｅ ｔｒａｎｓａｍｉｎａｓｅ、ＡＬＴ）、γ－グルタミルトランスペプチダーゼ（γ－Ｇｌｕｔａｍｙｌｔｒａｎｓｆｅｒａｓｅ、γ－ＧＴＰ）の血中への逸脱が抑制されることが期待される。 The liver function improving agent of the present invention is not particularly limited as long as it contains tectorigenins and other specific ingredients. Furthermore, the liver function improving agent of the present invention has an excellent liver function improving effect, and can be expected to enhance liver function or suppress liver damage. In particular, the combination of the tectorigenins of the present invention with certain other ingredients prevents damage to hepatocytes. This suppresses the escape of aspartate aminotransferase (AST), alanine transaminase (ALT), and γ-glutamyltranspeptidase (γ-GTP) in hepatocytes into the blood. It is expected that
本発明に用いられるテクトリゲニン類とは、テクトリゲニン、その配糖体又は誘導体、及びそれらの混合物を意味する。テクトリゲニン類は通常知られているテクトリゲニン類であれば特に限定されないが、テクトリゲニン（ｔｅｃｔｏｒｉｇｅｎｉｎ）、テクトリジン（ｔｅｃｔｏｒｉｄｉｎ）及びテクトリゲニン７－Ｏ－キシロシルグルコシド（ｔｅｃｔｏｒｉｇｅｎｉｎ ７－Ｏ－ｘｙｌｏｓｙｌｇｌｕｃｏｓｉｄｅ（ＴＧＸＧ）が好ましく、これらの混合物が特に好ましい。 Tectrigenins used in the present invention refer to tectorigenin, glycosides or derivatives thereof, and mixtures thereof. Tectorigenins are not particularly limited as long as they are commonly known tectrigenins, but tectorigenin, tectoridin, and tectorigenin 7-O-xylosylglucoside (TGXG) are preferred; Particularly preferred are mixtures of.
本発明に用いられるテクトリゲニン類は、合成されたものであっても植物に含まれるものであっても良いが、安全性等の観点から植物から抽出されたものが好ましく、アヤメ科やマメ科の植物から抽出したものが特に好ましい。アヤメ科植物やマメ科の植物としては、ハナショウブ、アヤメ、クズ、カキツバタ等が知られている。 The tectorigenins used in the present invention may be synthesized or contained in plants, but from the viewpoint of safety etc., those extracted from plants are preferable, Particularly preferred are those extracted from plants. Known examples of plants belonging to the iris family and leguminous family include iris, iris, kudzu, and kakitsubata.
テクトリゲニン類を植物から抽出する場合、植物の幹、枝、果実、葉、花、種子、樹皮、樹液、根、茎、芽等のいずれの部位を用いても構わないが、簡便に利用するには、葉や花を用いるとよい。抽出の際は、生のまま用いてもよいが、抽出効率を考えると、細切、乾燥、粉砕等の処理を行った後に抽出を行うことが好ましい。抽出は、抽出溶媒に浸漬するか、抽出効率を上げるため、撹拌や抽出溶媒中でホモジナイズしてもよい。抽出温度としては、５℃程度から抽出溶媒の沸点以下の温度とするのが適切である。抽出時間は抽出溶媒の種類や抽出温度によっても異なるが、１時間～３０日間程度とするのが適切である。 When extracting tectrigenins from plants, any part of the plant such as the trunk, branches, fruits, leaves, flowers, seeds, bark, sap, roots, stems, and buds may be used, but for convenience, It is best to use leaves and flowers. At the time of extraction, it may be used raw, but in consideration of extraction efficiency, it is preferable to perform extraction after performing treatments such as chopping, drying, and pulverizing. For extraction, the sample may be immersed in an extraction solvent, or may be stirred or homogenized in the extraction solvent to increase extraction efficiency. It is appropriate that the extraction temperature be from about 5° C. to a temperature below the boiling point of the extraction solvent. Although the extraction time varies depending on the type of extraction solvent and extraction temperature, it is appropriate to set it to about 1 hour to 30 days.
抽出溶媒としては、水の他、生理食塩水、リン酸緩衝液、リン酸緩衝生理食塩水等を用いてもよい。また、メタノール、エタノール、プロパノール、イソプロパノール等の低級アルコール、１、３－ブチレングリコール、プロピレングリコール、ジプロピレングリコール、グリセリン等の多価アルコール、エチルエーテル、プロピルエーテル等のエーテル類、酢酸エチル、酢酸ブチル等のエステル類、アセトン、エチルメチルケトン等のケトン類等の極性有機溶媒を用いることができ、これらより１種又は２種以上を選択して用いることができる。 As the extraction solvent, in addition to water, physiological saline, phosphate buffer, phosphate buffered saline, etc. may be used. In addition, lower alcohols such as methanol, ethanol, propanol, and isopropanol, polyhydric alcohols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and glycerin, ethers such as ethyl ether and propyl ether, ethyl acetate, and butyl acetate. Polar organic solvents such as esters such as esters, ketones such as acetone and ethyl methyl ketone can be used, and one or more types can be selected from these and used.
アヤメ科やマメ科の上記溶媒による抽出物に含まれるテクトリゲニン類は、そのままでも使用することができるが、濃縮、乾固した物を水や極性溶媒に再度溶解したり、或いはこれらの生理作用を損なわない範囲で脱色、脱臭、脱塩等の精製処理を行ったり、カラムクロマトグラフィー等による分画処理を行った後に用いてもよい。 The tectorigenins contained in the above-mentioned solvent extracts of Iridaceae and Fabaceae can be used as they are, but they can be concentrated and dried and then redissolved in water or a polar solvent, or their physiological effects can be It may be used after performing purification treatments such as decolorization, deodorization, desalting, etc., or fractionation treatment by column chromatography, etc., to the extent that no damage is caused.
本発明で用いるテクトリゲニン類の入手方法は上記の通り植物から抽出することもできるが、当業者に通常知られる方法により合成された合成物、市販品、該市販品を化学処理、酵素処理、精製処理等に供することによって得られた処理物等を用いてもよい。例えば、テクトリゲニン及びテクトリジンは関東化学社から得ることができる。 The tectorigenins used in the present invention can be obtained by extracting them from plants as described above, but they can also be synthesized by methods commonly known to those skilled in the art, commercially available products, chemically processed, enzymatically processed, purified. A treated product etc. obtained by subjecting to treatment etc. may be used. For example, tectorigenin and tectorizin can be obtained from Kanto Kagaku Co., Ltd.
テクトリゲニン類の含有量は特に限定されず、例えば、本発明の肝機能改善剤の全量に対して、０．０１質量％以上、好ましくは０．０５～２０質量％、より好ましくは０．１～１０質量％、特に好ましくは０．５～５質量％である。この場合のテクトリゲニン類の含有量とは、テクトリゲニン、テクトリジン及びＴＧＸＧの含有量の総量をいう。 The content of tectorigenins is not particularly limited, and is, for example, 0.01% by mass or more, preferably 0.05 to 20% by mass, more preferably 0.1 to 20% by mass, based on the total amount of the liver function improving agent of the present invention. 10% by weight, particularly preferably 0.5-5% by weight. The content of tectorigenins in this case refers to the total content of tectorigenin, tectorizin, and TGXG.
［他成分］
本発明の肝機能改善剤は、テクトリゲニン類と特定の他成分とを含有することを特徴とし、特定の他成分としては、肝機能改善能がほとんどないか、その能力が小さい他成分を、テクトリゲニン類と組み合わせることにより、肝機能改善能を相乗的に向上させることができる成分であれば限定されないが、特に以下に記載する（ａ）～（ｆ）からなる群より選ばれる少なくとも１種の成分とを含有することが望ましい。
[Other ingredients]
The liver function improving agent of the present invention is characterized by containing tectorigenins and specific other ingredients, and the specific other ingredients include other ingredients that have little or no ability to improve liver function. At least one component selected from the group consisting of (a) to (f) described below, although not limited as long as the component can synergistically improve the ability to improve liver function when combined with It is desirable to contain the following.
（ａ）ビタミン類
本発明の肝機能改善剤においては、テクトリゲニン類と共に、他成分として、ビタミンＢ２、パントテン酸ナトリウム、ビオチン、ビタミンＥから選ばれる少なくとも１種のビタミン類を用いることが好ましい。これらのビタミン類は、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。これらの他成分は、テクトリゲニン類と組み合わせた場合に、相乗的な肝機能改善作用が得られるだけでなく、テクトリゲニン類の呈味を改善することができる。さらに、テクトリゲニン類と組み合わせて飲料、錠剤とした際にテクトリゲニン類の体内への吸収性を高めることができる。
(a) Vitamins In the liver function improving agent of the present invention, it is preferable to use at least one vitamin selected from vitamin B2, sodium pantothenate, biotin, and vitamin E as other ingredients together with tectrigenins. These vitamins are not particularly limited, but commercially available vitamins used as raw materials for cosmetics and food and drink products can be used. When these other components are combined with tectorigenins, not only can a synergistic liver function improving effect be obtained, but also the taste of tectorigenins can be improved. Furthermore, when it is combined with tectorigenins to form a drink or tablet, the absorbability of tectorigenins into the body can be increased.
（ｂ）植物素材
本発明の肝機能改善剤においては、テクトリゲニン類と共に、他成分として、ヨモギ（Ａｒｔｅｍｉｓｉａ ｉｎｄｉｃａ）、黒ショウガ（Ｋａｅｍｐｆｅｒｉａ ｐａｒｖｉｆｌｏｒａ）、米ぬか、米胚芽から選ばれる少なくとも１種の植物素材を用いることが好ましい。これらの他成分は、テクトリゲニン類と組み合わせた場合に、相乗的な肝機能改善作用が得られるだけでなく、テクトリゲニン類の呈味を改善することができる。さらに、水にテクトリゲニン類のみを溶解した場合よりも、色味に優れ、また分散性に優れたものとすることができる。
(b) Plant material The liver function improving agent of the present invention contains at least one plant material selected from artemisia indica, black ginger (Kaempferia parviflora), rice bran, and rice germ as other ingredients in addition to tectorigenins. It is preferable to use When these other components are combined with tectorigenins, not only can a synergistic liver function improving effect be obtained, but also the taste of tectorigenins can be improved. Furthermore, it is possible to obtain better color and dispersibility than when only tectorigenins are dissolved in water.
これらの植物素材の中で、ヨモギと黒ショウガについては、花、葉、茎、根等、植物のいずれの部位であってもよいが、通常食用される部位が好ましく、植物素材そのもの（乾燥物を含む）、その粉砕物、搾汁、抽出物等を用いることができる。粉砕物としては、粉末、顆粒等が挙げられる。搾汁や抽出物は、液状であってもよいが、ペースト状や乾燥粉末として用いることもできる。抽出物は、適当な溶媒を用いて抽出することによって得ることができ、溶媒としては、例えば、水、エタノール、含水エタノールを用いることができる。 Among these plant materials, mugwort and black ginger can be any part of the plant such as flowers, leaves, stems, roots, etc., but normally edible parts are preferable, and the plant materials themselves (dried) can be used. ), its pulverized product, squeezed juice, extract, etc. can be used. Examples of the pulverized product include powder, granules, and the like. The squeezed juice or extract may be in liquid form, but it can also be used in the form of a paste or dry powder. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water, ethanol, and aqueous ethanol.
米ぬかは、米を精米した際に出る果皮、種皮、胚芽等を分離したものである。米ぬかとしては、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。 Rice bran is made by separating the pericarp, seed coat, germ, etc. that are produced when rice is milled. The rice bran is not particularly limited, but commercially available rice bran that is used as a raw material for cosmetics and food and drink products can be used.
米胚芽には、米の胚芽や胚芽に含まれる成分を単離したものが挙げられる。米胚芽としては、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。 Rice germ includes isolated rice germ and components contained in the germ. The rice germ is not particularly limited, but commercially available rice germs that are used as raw materials for cosmetics and food and drink products can be used.
（ｃ）発酵関連素材
本発明の肝機能改善剤においては、テクトリゲニン類と共に、他成分として、穀物麹、黒酢、小麦ふすま発酵エキス末、もろみ酢、ビール酵母から選ばれる少なくとも１種の発酵関連素材を用いることが好ましい。これらの他成分は、テクトリゲニン類と組み合わせた場合に、相乗的な肝機能改善作用が得られるだけでなく、テクトリゲニン類の呈味を改善することができる。さらに、水にテクトリゲニン類のみを溶解した場合よりも、色味に優れ、また分散性に優れたものとすることができる。
(c) Fermentation-related material In the liver function improving agent of the present invention, in addition to tectrigenins, at least one fermentation-related material selected from grain koji, black vinegar, fermented wheat bran extract powder, moromi vinegar, and brewer's yeast is used. It is preferable to use raw materials. When these other components are combined with tectorigenins, not only can a synergistic liver function improving effect be obtained, but also the taste of tectorigenins can be improved. Furthermore, it is possible to obtain better color and dispersibility than when only tectorigenins are dissolved in water.
これら発酵関連素材は、特に限定されないが、発酵関連素材をそのまま用いても良く、発酵関連素材を乾燥させて、粉砕したものを用いても良い。また、発酵関連素材から抽出したものであっても良く、抽出物をそのまま、或いは粉砕して用いることができる。粉砕物としては、粉末、顆粒等が挙げられる。抽出物は、液状であってもよいが、ペースト状や乾燥粉末として用いることもできる。抽出物は、適当な溶媒を用いて抽出することによって得ることができ、溶媒としては、例えば、水、エタノール、含水エタノールを用いることができる。 These fermentation-related materials are not particularly limited, but the fermentation-related materials may be used as they are, or the fermentation-related materials may be dried and pulverized. Moreover, it may be extracted from fermentation-related materials, and the extract can be used as it is or after being crushed. Examples of the pulverized product include powder, granules, and the like. The extract may be in liquid form, but it can also be used as paste or dry powder. The extract can be obtained by extraction using an appropriate solvent, and examples of the solvent that can be used include water, ethanol, and aqueous ethanol.
穀物麹は、大麦、アワ、ヒエ、キビ、タカキビ、紫黒米及び米粉の７つを麹菌を用いて発酵させたものであり、黒酢、小麦ふすま発酵エキス末、もろみ酢、ビール酵母は、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。 Grain koji is made by fermenting seven ingredients: barley, millet, millet, Japanese millet, purple black rice, and rice flour using koji mold.Black vinegar, wheat bran fermented extract powder, moromi vinegar, and brewer's yeast are especially Although not limited, commercially available materials used as raw materials for cosmetics and food and drink products can be used.
穀物麹、黒酢、小麦ふすま発酵エキス末、もろみ酢の発酵に使用する麹は、特に限定されないが、米、麦、大豆、アワ、ヒエ、キビ等の穀物を麹菌で発酵させたものであれば良く、発酵に用いる麹菌としては、黄麹菌、青麹菌、白麹菌、黒麹菌、紅麹等のいずれを用いても良い。具体的には、アスペルギルス・アワモリ（Ａｓｐｅｒｇｉｌｌｕｓ ａｗａｍｏｒｉ）（黒麹菌）、アスペルギルス・サイトイ（Ａｓｐｅｒｇｉｌｌｕｓ ｓａｉｔｏｉ）（黒麹菌）、アスペルギルス・ナカザワイ（Ａｓｐｅｒｇｉｌｌｕｓ ｎａｋａｚａｗａｉ）(黒麹菌)、アスペルギルス・ウサミ（Ａｓｐｅｒｇｉｌｌｕｓ ｕｓａｍｉｉ）（黒麹菌）、アスペルギルス・ルーチェンシス（Ａｓｐｅｒｇｉｌｌｕｓ ｌｕｃｈｅｎｓｉｓ）（黒麹菌）、アスペルギルス・ニガー（Ａｓｐｅｒｇｉｌｌｕｓ ｎｉｇｅｒ）（黒麹菌）、アスペルギルス・カワチ（Ａｓｐｅｒｇｉｌｌｕｓ ｋａｗａｃｈｉｉ）（白麹菌）、アスペルギルス・オリゼー（Ａｓｐｅｒｇｉｌｌｕｓ ｏｒｙｚａｅ）（黄麹菌）等のアスペルギルス属に属する微生物を挙げることができる。 The koji used for fermentation of grain koji, black vinegar, fermented wheat bran extract powder, and moromi vinegar is not particularly limited, but may be one made by fermenting grains such as rice, barley, soybeans, millet, millet, millet, etc. with koji mold. As the koji mold used for fermentation, any of yellow koji mold, blue koji mold, white koji mold, black koji mold, red koji mold, etc. may be used. Specifically, Aspergillus awamori (black koji mold), Aspergillus saitoi (black koji mold), Aspergillus nakazawai (black koji mold), Aspergillus saitoi (black koji mold), Rabbit (Aspergillus usamii) (black Aspergillus luchensis (black koji mold), Aspergillus niger (black koji mold), Aspergillus kawachii (white koji mold), Aspergillus ori Aspergillus oryzae (yellow koji mold) Examples include microorganisms belonging to the genus Aspergillus such as.
（ｄ）アミノ酸
本発明の肝機能改善剤においては、テクトリゲニン類と共に、他成分として、アラニン、イソロイシン、リジン、プロリン、チロシンから選ばれる少なくとも１種のアミノ酸を用いることが好ましい。塩としては、例えば、ナトリウム塩、塩酸塩等を挙げることができる。これらのアミノ酸類は、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。これらの他成分は、テクトリゲニン類と組み合わせた場合に、相乗的な肝機能改善作用が得られるだけでなく、テクトリゲニン類の呈味を改善することができる。さらに、水にテクトリゲニン類のみを溶解した場合よりも、色味に優れ、また分散性に優れたものとすることができる。
(d) Amino acids In the liver function improving agent of the present invention, it is preferable to use at least one amino acid selected from alanine, isoleucine, lysine, proline, and tyrosine as another component together with tectorigenins. Examples of the salt include sodium salt, hydrochloride, and the like. These amino acids are not particularly limited, but commercially available amino acids that are used as raw materials for cosmetics and food and drink products can be used. When these other components are combined with tectorigenins, not only can a synergistic liver function improving effect be obtained, but also the taste of tectorigenins can be improved. Furthermore, it is possible to obtain better color and dispersibility than when only tectorigenins are dissolved in water.
（ｅ）機能性添加剤
本発明の肝機能改善剤においては、テクトリゲニン類と共に、他成分として、鉄、モリブデン、亜鉛、チタン、没食子酸、クロロゲン酸、クルクミン、カフェイン、Ｌ－カルニチン、α‐リポ酸から選ばれる少なくとも１種の機能性添加剤を用いることが好ましい。
これらの機能性添加剤は、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。これらの他成分は、テクトリゲニン類と組み合わせた場合に、相乗的な肝機能改善作用が得られるだけでなく、テクトリゲニン類の呈味を改善することができる。さらに、水にテクトリゲニン類のみを溶解した場合よりも、色味に優れ、また分散性に優れたものとすることができる。
(e) Functional additives In the liver function improving agent of the present invention, in addition to tectrigenins, other ingredients include iron, molybdenum, zinc, titanium, gallic acid, chlorogenic acid, curcumin, caffeine, L-carnitine, α- It is preferable to use at least one functional additive selected from lipoic acid.
These functional additives are not particularly limited, but commercially available ones that are used as raw materials for cosmetics and food and drink products can be used. When these other components are combined with tectorigenins, not only can a synergistic liver function improving effect be obtained, but also the taste of tectorigenins can be improved. Furthermore, it is possible to obtain better color and dispersibility than when only tectorigenins are dissolved in water.
（ｆ）甘味料
本発明の肝機能改善剤においては、テクトリゲニン類と共に、他成分として、アスパルテーム、麦芽糖、フラクトオリゴ糖から選ばれる少なくとも１種の甘味料を用いることが好ましい。これらの甘味料は、特に限定されないが、化粧品や飲食品の原料として利用される市販のものを用いることができる。これらの他成分は、テクトリゲニン類と組み合わせた場合に、相乗的な肝機能改善作用が得られるだけでなく、テクトリゲニン類の呈味を改善することができる。さらに、水にテクトリゲニン類のみを溶解した場合よりも、色味に優れ、また分散性に優れたものとすることができる。
(f) Sweetener In the liver function improving agent of the present invention, it is preferable to use at least one sweetener selected from aspartame, maltose, and fructo-oligosaccharides together with tectorigenins as another component. These sweeteners are not particularly limited, but commercially available sweeteners used as raw materials for cosmetics and food and drink products can be used. When these other components are combined with tectorigenins, not only can a synergistic liver function improving effect be obtained, but also the taste of tectorigenins can be improved. Furthermore, it is possible to obtain better color and dispersibility than when only tectorigenins are dissolved in water.
[使用の形態]
本発明の肝機能改善剤は、肝機能改善の用途に用いられる点において、製品として他の製品と区別できるものであればよく、例えば、本発明の肝機能改善剤に係る製品の本体、包装、説明書、宣伝物のいずれかに肝機能改善の機能がある旨を表示したものを挙げることができる。肝機能改善機能がある旨の表示とは、例えば、肝臓の健康を維持したい方、肝臓の健康を維持する、肝臓の働きをサポートする、肝臓の健康に、肝臓機能の改善に、といったように肝臓の健康の維持増進に役立つことの表示や、肝機能が気になる方、肝臓の健康が気になる方、お酒をよく飲む方、といったように肝臓の働きを気にする対象者に訴えかける表示をいう。
[Form of use]
The liver function improving agent of the present invention may be a product that can be distinguished from other products in that it is used for improving liver function, such as the main body and packaging of the product related to the liver function improving agent of the present invention. Examples include those that indicate in their instructions or promotional materials that they have the ability to improve liver function. Labeling that it has the ability to improve liver function means, for example, for people who want to maintain liver health, to maintain liver health, to support liver function, to liver health, to improving liver function. Displays that it helps maintain and improve liver health, and targets people who are concerned about liver function, such as those who are concerned about liver function, liver health, and those who drink alcohol frequently. A display that appeals to others.
本発明の肝機能改善剤の利用形態としては、具体的には、医薬品（医薬部外品を含む）、化粧品、一般食品、栄養機能食品の他、消費者庁により効能の表示が認められた特定保健用食品、機能性表示食品等のいわゆる健康食品を挙げることができる。 Specifically, the liver function improving agent of the present invention can be used in pharmaceuticals (including quasi-drugs), cosmetics, general foods, nutritionally functional foods, and other products that have been approved for efficacy labeling by the Consumer Affairs Agency. Examples include so-called health foods such as foods for specified health uses and foods with functional claims.
本発明の肝機能改善剤は、外用又は経口用として使用することができる。外用剤としては、皮膚、頭皮等に塗布して用いるものであれば、特に制限はなく、その形態としては、軟膏剤、クリーム剤、ジェル剤、ローション剤、乳液剤、パック剤、湿布剤等の皮膚外用剤や、注射剤等の形態を挙げることができる。 The liver function improving agent of the present invention can be used externally or orally. External preparations are not particularly limited as long as they are applied to the skin, scalp, etc., and their forms include ointments, creams, gels, lotions, emulsions, packs, poultices, etc. Forms such as external skin preparations and injections can be mentioned.
また、本発明の肝機能改善剤を経口剤として用いる場合、その形態としては、例えば、錠剤、カプセル剤、粉末剤、顆粒剤、液剤、粒状剤、棒状剤、板状剤、ブロック状剤、固形状剤、丸状剤、ペースト状剤、クリーム状剤、カプレット状剤、ゲル状剤、チュアブル状剤、スティック状剤等を挙げることができる。これらの中でも、錠剤、カプセル剤、粉末剤、顆粒剤、液剤の形態が、摂取がしやすく肝機能改善作用を得やすいことから特に好ましい。具体的には、サプリメント、食品添加剤、ペットボトル、缶、瓶等に充填された容器詰飲料、水（湯）、牛乳、果汁等に溶解して飲むためのインスタント粉末（顆粒）飲料等を例示することができる。これらは食事の際等に手軽に飲食しやすく、また嗜好性を高めることができるという点で好ましい。 In addition, when the liver function improving agent of the present invention is used as an oral preparation, its forms include, for example, tablets, capsules, powders, granules, liquids, granules, rods, plates, blocks, etc. Examples include solid preparations, pills, paste preparations, cream preparations, caplet preparations, gel preparations, chewable preparations, and stick preparations. Among these, the forms of tablets, capsules, powders, granules, and liquids are particularly preferable because they are easy to ingest and provide liver function-improving effects. Specifically, supplements, food additives, packaged beverages filled in plastic bottles, cans, bottles, etc., instant powder (granule) beverages that can be dissolved in water (hot water), milk, fruit juice, etc. I can give an example. These are preferable because they are easy to eat and drink during meals and can enhance palatability.
本発明の肝機能改善剤におけるテクトリゲニン類及び他成分の含有量としては、その効果の奏する範囲で適宜含有させればよい。本発明の肝機能改善剤は、テクトリゲニン類を有効成分とするものであってもよく、テクトリゲニン類と他成分とを有効成分とするものであってもよい。 The contents of tectorigenins and other components in the liver function improving agent of the present invention may be appropriately contained within the range where their effects can be achieved. The liver function improving agent of the present invention may contain tectrigenins as an active ingredient, or may contain tectrigenins and other ingredients as active ingredients.
一般的には、本発明の肝機能改善剤が医薬品やサプリメント（錠剤、カプセル剤）の場合には、テクトリゲニン類及び他成分が乾燥質量換算で全体の０．０１～１００質量％含まれていることが好ましく、０．１～８５質量％含まれていることがより好ましく、０．５～７０質量％含まれていることがさらに好ましい。 Generally, when the liver function improving agent of the present invention is a drug or supplement (tablet, capsule), tectorigenins and other components are contained in an amount of 0.01 to 100% by mass of the total on a dry mass basis. The content is preferably from 0.1 to 85% by mass, and even more preferably from 0.5 to 70% by mass.
本発明の肝機能改善剤が容器詰飲料（液剤）である場合には、テクトリゲニン類及び他成分が乾燥質量換算で全体の０．０００１～１０質量％含まれていることが好ましく、０．０００３～６質量％含まれていることがより好ましく、０．０００５～４質量％含まれていることがさらに好ましい。 When the liver function improving agent of the present invention is a packaged beverage (liquid), it is preferable that tectorigenins and other components be contained in an amount of 0.0001 to 10% by mass of the total in terms of dry mass, and 0.0003% by mass of the total. It is more preferable that the content is from 6% by mass, and even more preferably from 0.0005 to 4% by mass.
また、本発明の肝機能改善剤がインスタント粉末飲料（粉末剤）、インスタント顆粒飲料（顆粒剤）である場合には、テクトリゲニン類及び他成分が乾燥質量換算で全体の０．００１～５０質量％含まれていることが好ましく、０．０１～４０質量％含まれていることがより好ましく、０．１～３０質量％含まれていることがさらに好ましい。 In addition, when the liver function improving agent of the present invention is an instant powder drink (powder) or an instant granule drink (granule), tectorigenins and other components are 0.001 to 50% by mass of the total in terms of dry mass. It is preferably contained, more preferably 0.01 to 40% by mass, and even more preferably 0.1 to 30% by mass.
本発明の効果をより有効に発揮させるためには、テクトリゲニン類及び他成分が乾燥質量換算で本発明の肝機能改善剤全体（水分を除く）の８０質量％以上含まれていることが好ましく、９０質量％以上含まれていることがより好ましく、９５質量％以上含まれていることがさらに好ましく、１００質量％であることが特に好ましい。さらに、本発明の肝機能改善剤が成分（ａ）～（ｆ）のいずれかを含有する場合、その含有される成分は、本発明に記載される他成分のみで構成されることが好ましい。すなわち、本発明の肝機能改善剤が例えば成分（ａ）植物素材を含有する場合には、それ以外の飲料用植物素材を含まないように構成することが好ましい。 In order to more effectively exhibit the effects of the present invention, it is preferable that tectorigenins and other components contain 80% by mass or more of the entire liver function improving agent of the present invention (excluding water) in terms of dry mass, It is more preferable that the content is 90% by mass or more, even more preferably 95% by mass or more, and particularly preferably 100% by mass. Furthermore, when the liver function improving agent of the present invention contains any of the components (a) to (f), it is preferable that the contained components consist only of the other components described in the present invention. That is, when the liver function improving agent of the present invention contains, for example, the component (a) plant material, it is preferable to configure it so that it does not contain any other drinkable plant material.
本発明の肝機能改善剤の摂取量としては特に制限はないが、本発明の効果をより顕著に発揮させる観点から、１日当たりのテクトリゲニン類及び他成分の摂取量が、５ｍｇ／日以上となるように摂取することが好ましく、１０ｍｇ／日以上となるように摂取することがより好ましく、２０ｍｇ／日以上となるように摂取することがさらに好ましい。その上限は特に制限されないが、例えば、２ｇ／日であり、好ましくは１ｇ／日である。本発明の肝機能改善剤は、1日の摂取量が前記摂取量となるように、１つの容器に、又は例えば２～３の複数の容器に分けて、1日分として収容することができる。 There is no particular restriction on the intake amount of the liver function improving agent of the present invention, but from the viewpoint of exhibiting the effects of the present invention more markedly, the daily intake of tectorigenins and other components should be 5 mg/day or more. It is preferable to take in an amount of 10 mg/day or more, more preferably to take an amount of 20 mg/day or more. The upper limit is not particularly limited, but is, for example, 2 g/day, preferably 1 g/day. The liver function improving agent of the present invention can be stored in one container or divided into, for example, 2 to 3 containers, so that the daily intake amount is the above-mentioned intake amount. .
テクトリゲニン類及び他成分の配合質量比としては、乾燥質量換算で、０．０００１：１～６０：１の範囲であることが好ましく、０．０００５：１～５０：１の範囲であることがより好ましく、０．００１：１～４０：１の範囲であることがさらに好ましく、０．００３：１～３０：１の範囲であることが特に好ましい。テクトリゲニン類及び他成分の配合比が、上記範囲であることにより、本発明の効果をより有効に発揮することができる。 The blended mass ratio of tectorigenins and other components is preferably in the range of 0.0001:1 to 60:1, more preferably in the range of 0.0005:1 to 50:1, in terms of dry mass. It is preferably in the range of 0.001:1 to 40:1, more preferably in the range of 0.003:1 to 30:1. When the blending ratio of tectorigenins and other components is within the above range, the effects of the present invention can be more effectively exhibited.
本発明の肝機能改善剤は、必要に応じて、経口用として許容される添加剤や、テクトリゲニン類及び他成分以外の成分を添加して、公知の製剤方法によって製造することができる。 The liver function improving agent of the present invention can be produced by a known formulation method by adding orally acceptable additives and components other than tectorigenins and other components, if necessary.
また、本発明の肝機能改善剤としては、テクトリゲニン類及び他成分を含有する肝機能改善用食品の他、食品に対してテクトリゲニン類及び他成分を添加して得た肝機能改善用食品を挙げることができ、例えば、通常の食品（天然の食品を含む）に比して本発明のテクトリゲニン類及び他成分含有量を増加させた食品や、本発明のテクトリゲニン類及び他成分を通常含まない食品に対してテクトリゲニン類及び他成分を添加した食品を挙げることができる。テクトリゲニン類及び他成分の添加は、それぞれの成分を別々に添加してもよいし、同時に添加してもよく、また、テクトリゲニン類及び他成分以外の他成分と共に添加してもよい。 In addition, examples of the liver function improving agent of the present invention include foods for improving liver function containing tectorigenins and other ingredients, as well as foods for improving liver function obtained by adding tectrigenins and other ingredients to foods. For example, foods that have an increased content of the tectorigenins and other ingredients of the present invention compared to normal foods (including natural foods), and foods that do not normally contain the tectorigenins and other ingredients of the present invention. Examples include foods to which tectorigenins and other ingredients have been added. The tectorigenins and other components may be added separately or simultaneously, or may be added together with other components other than the tectorigenins and other components.
本発明の肝機能改善剤の使用形態の一つとして、食品に添加することができ、食品としては、例えば、炭酸飲料、栄養飲料、果実飲料、乳酸飲料、スムージー、青汁等の飲料；アイスクリーム、アイスシャーベット、かき氷等の冷菓；そば、うどん、はるさめ、中華麺、即席麺等の麺類；飴、キャンディー、ガム、チョコレート、錠菓、スナック菓子、ビスケット、ゼリー、ジャム、クリーム、焼き菓子、パン等の菓子類；かまぼこ、ハム、ソーセージ等の水産・畜産加工食品；加工乳、発酵乳、ヨーグルト等の乳製品；サラダ油、てんぷら油、マーガリン、マヨネーズ、ショートニング、ホイップクリーム、ドレッシング等の油脂及びその加工食品；ソース、醤油等の調味料；カレー、シチュー、親子丼、お粥、雑炊、中華丼、かつ丼、天丼、牛丼、ハヤシライス、オムライス、おでん、マーボドーフ、餃子、シューマイ、ハンバーグ、ミートボール、各種ソース、各種スープ等のレトルトパウチ食品等を挙げることができる。 As one of the usage forms of the liver function improving agent of the present invention, it can be added to foods, and examples of foods include drinks such as carbonated drinks, nutritional drinks, fruit drinks, lactic acid drinks, smoothies, green juices, etc.; Frozen desserts such as cream, ice sorbet, and shaved ice; Noodles such as soba, udon, harukame, Chinese noodles, and instant noodles; candy, candy, gum, chocolate, tablets, snacks, biscuits, jelly, jam, cream, baked goods, and bread Confectionery products such as fish cakes, ham, sausages, etc.; Dairy products such as processed milk, fermented milk, and yogurt; Fats and oils such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipped cream, and dressings; Processed foods; seasonings such as sauces and soy sauce; curry, stew, oyakodon, rice porridge, rice porridge, Chinese bowl, katsudon, tempura bowl, gyudon, hayashi rice, omelet rice, oden, marbodorf, gyoza, shumai, hamburger steak, meatballs Examples include retort pouch foods such as , various sauces, and various soups.
以下、本発明を実施例に基づき説明する。 Hereinafter, the present invention will be explained based on examples.
［試験例］
テクトリゲニン類としては、植物から抽出したテクトリゲニン、テクトリジン及びＴＧＸＧの混合物を用いた。（テクトリゲニン：テクトリジン：ＴＧＸＧ＝５．４：３４．１：６０．５）
[Test example]
As the tectrigenin, a mixture of tectorigenin, tectorizin, and TGXG extracted from plants was used. (Tectorigenin: Tectorizin: TGXG = 5.4:34.1:60.5)
［肝機能改善確認試験］
（サンプル液の調製）
ヒト肝癌由来細胞(HepG2)を10%FBS-DMEM（以下DMEM）により培養後、96well plateの各wellに4.0×104cells/wellの細胞密度で播種し、37℃、5%CO２インキュベーター内で24時間前培養した。
上記細胞にDMEMを用いて後述の表１～６に記載する所定濃度に調製したサンプル液を200μLずつ添加し、5%CO２インキュベーター内で24時間培養した。
なお、上記サンプル液の調製において、他成分としてビタミンE、黒ショウガ、クルクミン、又はα-リポ酸を添加した際は、各被験物質DMSOに溶解し、DMSOの終濃度が0.25％になるように調製した。
[Liver function improvement confirmation test]
(Preparation of sample liquid)
Human liver cancer-derived cells (HepG2) were cultured in 10% FBS-DMEM (hereinafter referred to as DMEM), then seeded in each well of a 96-well plate at a cell density of 4.0 × 10 4 cells/well, and incubated at 37°C in a 5% CO 2 incubator. The cells were pre-incubated for 24 hours.
To the above cells, 200 μL of each sample solution prepared using DMEM to a predetermined concentration listed in Tables 1 to 6 below was added, and the cells were cultured in a 5% CO 2 incubator for 24 hours.
In addition, when preparing the above sample solution, when adding vitamin E, black ginger, curcumin, or α-lipoic acid as other ingredients, dissolve each test substance in DMSO so that the final concentration of DMSO is 0.25%. Prepared.
（測定方法）
サンプル液の培地を除去し、DMEMで30倍に希釈したCell Counting Kit-8溶液を150μＬ添加した。37℃、5％CO２インキュベーター内に静置し適度に発色させた後、450 nmにおける吸光度を測定した。
コントロールには、試験物質をDMSOに溶解したものに対しては0.25%DMSO含有DMEM、その他の試験物質に対してはDMEMを用いた。
(Measuring method)
The culture medium of the sample solution was removed, and 150 μL of Cell Counting Kit-8 solution diluted 30 times with DMEM was added. After standing in a 5% CO 2 incubator at 37°C to allow appropriate color development, absorbance at 450 nm was measured.
As a control, DMEM containing 0.25% DMSO was used for the test substance dissolved in DMSO, and DMEM was used for the other test substances.
各試験物質の肝細胞賦活率は下記の式にて算出した。
肝細胞賦活率（％）
% of control = (Data sample－Data blank) ／（Data control－Data blank）×100
（式中、Data sample：試験溶液(test)の蛍光強度
Data control：コントロール(test)の蛍光強度
Data blank：試験溶液(blank)の蛍光強度）
The hepatocyte activation rate of each test substance was calculated using the following formula.
Hepatocyte activation rate (%)
% of control = (Data sample－Data blank) / (Data control－Data blank) × 100
(In the formula, Data sample: Fluorescence intensity of test solution (test)
Data control: Control (test) fluorescence intensity
Data blank: Fluorescence intensity of test solution (blank))
その結果を表１～表６に示す。各試験区の肝細胞賦活率以外の数値はテクトリゲニン類又は他成分の最終濃度を示し、単位はいずれもμｇ／ｍＬである。各試験区の肝細胞賦活率はコントロールの肝細胞賦活率に対する変化値を示している。 The results are shown in Tables 1 to 6. The numerical values other than the hepatocyte activation rate in each test group indicate the final concentration of tectorigenins or other components, and the units are μg/mL. The hepatocyte activation rate of each test group shows the change value with respect to the hepatocyte activation rate of the control.
なお、テクトリゲニン類を単独で用いた場合の肝細胞賦活率（変化値）と、他成分を単独で用いた場合の肝細胞賦活率（変化値）の和よりも、組み合わせて用いた場合の肝細胞賦活率（変化値）が１０ポイント以上増加した他成分をテクトリゲニン類との相乗効果ありとし、表１～表６に記載した。 Furthermore, the hepatocyte activation rate (change value) when using tectrigenins alone and the hepatocyte activation rate (change value) when using other ingredients alone is higher than the sum of the hepatocyte activation rate (change value) when using tectrigenins alone. Other ingredients whose cell activation rate (change value) increased by 10 points or more were considered to have a synergistic effect with tectorigenins and are listed in Tables 1 to 6.
表１に記載された他成分はすべて市販されているものを用いた。 All other components listed in Table 1 were commercially available.
表２のヨモギは市販されているヨモギの粉砕末、黒ショウガは市販されている黒ショウガ根茎の６０％エタノール抽出物を用いた。また、ヨモギ及び黒ショウガ以外の他成分はすべて市販されているものを用いた。 The mugwort in Table 2 was a commercially available ground powder of mugwort, and the black ginger was a commercially available 60% ethanol extract of black ginger rhizome. In addition, all other ingredients other than mugwort and black ginger were commercially available.
表３に記載された他成分はすべて市販されているものを用いた。 All other components listed in Table 3 were commercially available.
表４に記載された他成分はすべて市販されているものを用いた。 All other components listed in Table 4 were commercially available.
表５に記載された他成分はすべて市販されているものを用いた。なお、鉄は塩化鉄、モリブデンは塩化モリブデン、チタンは二酸化チタン、亜鉛はグルコン酸亜鉛を用いた。 All other components listed in Table 5 were commercially available. In addition, iron chloride was used for iron, molybdenum chloride was used for molybdenum, titanium dioxide was used for titanium, and zinc gluconate was used for zinc.
表６に記載された他成分はすべて市販されているものを用いた。 All other components listed in Table 6 were commercially available.
表１～表６に示すように、テクトリゲニン類と本発明の特定の他成分を組み合わせることにより、肝細胞賦活率が相乗的に増加した。したがって、本発明の肝機能改善剤は肝血流の増加、胆汁分泌促進、肝臓組織呼吸促進、又はウィルス性・薬剤性・アルコール性肝障害抑制を目的として利用できる。 As shown in Tables 1 to 6, the hepatocyte activation rate increased synergistically by combining tectorigenins with specific other components of the present invention. Therefore, the liver function improving agent of the present invention can be used for the purpose of increasing hepatic blood flow, promoting bile secretion, promoting liver tissue respiration, or suppressing viral, drug-induced, and alcohol-induced liver damage.
（比較例）
実施例と同じ手法を用いて、下記他成分の肝機能改善確認試験を行ったところ、ビタミン類であるビタミンＡ（テクトリゲニン）、植物素材である大麦若葉末、発酵関連素材である野菜発酵物、アミノ酸であるアルギニン、機能性添加剤であるカルシウム及び甘味料であるトレハロースについては、いずれもテクトリゲニン類を単独で用いた場合の肝細胞賦活率（変化値）と、他成分を単独で用いた場合の肝細胞賦活率（変化値）の和よりも、組み合わせて用いた場合の肝細胞賦活率（変化値）が１０ポイント以上増加せず、肝細胞賦活の相乗作用は確認されなかった。
(Comparative example)
Using the same method as in the example, we conducted a liver function improvement confirmation test for the following other ingredients: vitamin A (tectorigenin), a plant material such as barley grass powder, fermented vegetable material as a fermentation-related material, Regarding the amino acid arginine, the functional additive calcium, and the sweetener trehalose, the hepatocyte activation rate (change value) when using tectorigenins alone and when other ingredients are used alone. The hepatocyte activation rate (change value) when used in combination did not increase by 10 points or more than the sum of the hepatocyte activation rates (change value) of , and no synergistic effect of hepatocyte activation was confirmed.
（配合例１：化粧水）
全体を１００質量部として、テクトリゲニン類 ０．０１質量部、ビタミンＢ２ ０．０１質量部、グリセリン １０質量部、ジグリセリン ３質量部、１、３－ブチレングリコール １２質量部、ペンチレングリコール ３質量部、ヒアルロン酸ナトリウム ０．１質量部、クエン酸 ０．０１質量部、クエン酸ナトリウム ０．０２質量部、キサンタンガム ０．１質量部、メチルパラベン ０．１５質量部、カルボマー ０．２質量部、水酸化ナトリウム ０．０３質量部及び水 残部を混合して、化粧水の態様で本発明の肝機能改善剤を調製した。
(Formulation example 1: Lotion)
The total is 100 parts by mass, 0.01 parts by mass of tectrigenins, 0.01 parts by mass of vitamin B2, 10 parts by mass of glycerin, 3 parts by mass of diglycerin, 12 parts by mass of 1,3-butylene glycol, 3 parts by mass of pentylene glycol. , sodium hyaluronate 0.1 part by mass, citric acid 0.01 part by mass, sodium citrate 0.02 part by mass, xanthan gum 0.1 part by mass, methylparaben 0.15 part by mass, carbomer 0.2 part by mass, hydroxide The liver function improving agent of the present invention was prepared in the form of a lotion by mixing 0.03 parts by mass of sodium and the remainder of water.
（配合例２：シャンプー）
全体を１００質量部として、テクトリゲニン類 ０．０１質量部、ヨモギ葉エキス ０．０２質量部、ラウレス硫酸ナトリウム ７．５質量部、コカミドプロピルベタイン ４．２質量部、コカミドＤＥＡ ３質量部、１、３－ブチレングリコール ０．１質量部、ポリクオタニウム－１０ ０．２２５質量部、クエン酸 ０．１５質量部、クエン酸ナトリウム ０．０５質量部、フェノキシエタノール ０．９質量部及び水 残部を混合して、シャンプーの態様で本発明の肝機能改善剤を調製した。
(Formulation example 2: Shampoo)
Taking the total as 100 parts by mass, 0.01 parts by mass of tectrigenins, 0.02 parts by mass of mugwort leaf extract, 7.5 parts by mass of sodium laureth sulfate, 4.2 parts by mass of cocamidopropyl betaine, 3 parts by mass of cocamide DEA, 1 , 0.1 part by mass of 3-butylene glycol, 0.225 parts by mass of polyquaternium-10, 0.15 parts by mass of citric acid, 0.05 parts by mass of sodium citrate, 0.9 parts by mass of phenoxyethanol, and the remainder of water. The liver function improving agent of the present invention was prepared in the form of a shampoo.
（配合例３：石鹸）
全体を１００質量部として、テクトリゲニン類 ０．５質量部、黒酢 ０．５重量部、グリセリン ２質量部、オリーブ油 １質量部、ＥＤＴＡ－４ナトリウム ０．１質量部、エチドロン酸４ナトリウム ０．２質量部及び石鹸素地 残部を混合及び固化することにより、石鹸の態様で本発明の肝機能改善剤を調製した。
(Formulation example 3: Soap)
The total is 100 parts by mass, 0.5 parts by mass of tectrigenins, 0.5 parts by mass of black vinegar, 2 parts by mass of glycerin, 1 part by mass of olive oil, 0.1 parts by mass of sodium EDTA-4, 0.2 parts by mass of tetrasodium etidronate. The liver function improving agent of the present invention was prepared in the form of a soap by mixing and solidifying the parts by mass and the remainder of the soap base.
（配合例４：乳液）
全体を１００質量部として、テクトリゲニン類 ０．１質量部、チロシン ０．１質量部、ショ糖脂肪酸エステル ３質量部、グリセリン １２質量部、スクアラン ６質量部、ジメチルシリコーンオイル ２４質量部、ポリプロピレングリコール １質量部、増粘剤 ０．０６質量部、フェノキシエタノール ０．２質量部、エタノール ５質量部、水酸化ナトリウム ０．０１質量部及び精製水 残部を混合して、乳液の態様で本発明の肝機能改善剤を調製した。
(Formulation example 4: Emulsion)
The total is 100 parts by mass, 0.1 part by mass of tectrigenins, 0.1 part by mass of tyrosine, 3 parts by mass of sucrose fatty acid ester, 12 parts by mass of glycerin, 6 parts by mass of squalane, 24 parts by mass of dimethyl silicone oil, 1 part by mass of polypropylene glycol. Parts by mass, 0.06 parts by mass of thickener, 0.2 parts by mass of phenoxyethanol, 5 parts by mass of ethanol, 0.01 parts by mass of sodium hydroxide, and the remainder of purified water were mixed to form a milky lotion. An improvement agent was prepared.
（配合例５：化粧用クリーム）
全体を１００質量部として、テクトリゲニン類 ０．１質量部、クロロゲン酸 ０．１質量部、スクワラン １５．０質量部、ミリスチン酸オクチルドデシル ４．０質量部、水素添加大豆リン脂質 ０．２質量部、ブチルアルコール ２．４質量部、硬化油 １．５質量部、ステアリン酸 １．５質量部、親油型モノステアリン酸グリセリン １．５質量部、モノステアリン酸ポリグリセリル ０．５質量部、ベヘニルアルコール ０．８質量部、モノミリスチン酸ポリグリセリル ０．７質量部、サラシミツロウ ０．３質量部、ｄ－δ－トコフェロール ０．１質量部、メチルパラベン ０．３質量部、Ｃ１０～３０アルキル変性カルボキシビニルポリマー ０．２質量部、カルボキシビニルポリマー ０．１質量部、１、３－ブタンジオール １８．０質量部、水酸化ナトリウム ０．１質量部及び精製水 残部を混合して、化粧用クリームの態様で本発明の肝機能改善剤を調製した。
(Formulation example 5: Cosmetic cream)
When the total is 100 parts by mass, 0.1 part by mass of tectrigenins, 0.1 part by mass of chlorogenic acid, 15.0 parts by mass of squalane, 4.0 parts by mass of octyldodecyl myristate, 0.2 parts by mass of hydrogenated soybean phospholipid. , butyl alcohol 2.4 parts by mass, hydrogenated oil 1.5 parts by mass, stearic acid 1.5 parts by mass, lipophilic glyceryl monostearate 1.5 parts by mass, polyglyceryl monostearate 0.5 parts by mass, behenyl alcohol 0 .8 parts by mass, polyglyceryl monomyristate 0.7 parts by mass, beeswax 0.3 parts by mass, d-δ-tocopherol 0.1 parts by mass, methylparaben 0.3 parts by mass, C10-30 alkyl-modified carboxyvinyl polymer 0 .2 parts by mass, 0.1 parts by mass of carboxyvinyl polymer, 18.0 parts by mass of 1,3-butanediol, 0.1 parts by mass of sodium hydroxide, and the remainder of purified water were mixed and prepared in the form of a cosmetic cream. A liver function improving agent of the invention was prepared.
（配合例６：パック剤）
全体を１００質量部として、テクトリゲニン類抽出物 ０．１質量部、アスパルテーム ０．０１質量部、ポリビニルアルコール ２０．０質量部、グリセリン ５．０質量部、エタノール ２０．０質量部、カオリン ６．０質量部、防腐剤 ０．２質量部、香料 ０．１質量部及び精製水 残部を混合して、パック剤の態様で本発明の肝機能改善剤を調製した。
(Formulation example 6: pack agent)
Taking the total as 100 parts by mass, tectorigenin extract 0.1 part by mass, aspartame 0.01 part by mass, polyvinyl alcohol 20.0 parts by mass, glycerin 5.0 parts by mass, ethanol 20.0 parts by mass, kaolin 6.0 parts by mass. The liver function improving agent of the present invention was prepared in the form of a pack by mixing parts by mass, 0.2 parts by mass of preservative, 0.1 part by mass of perfume, and the remainder of purified water.
（配合例７：錠剤）
全体を１００質量部として、テクトリゲニン類粉末 ５質量部、パントテン酸ナトリウム ８質量部、ビタミンＢ１ ５質量部、結晶性セルロース ２０質量部、乳糖 ５０質量部、ステアリン酸マグネシウム ４質量部及びコーンスターチ 残部を混合及び打錠することにより、錠剤の態様で本発明の肝機能改善剤を調製した。
(Formulation example 7: tablet)
The total amount is 100 parts by mass, and 5 parts by mass of tectorigenin powder, 8 parts by mass of sodium pantothenate, 5 parts by mass of vitamin B1, 20 parts by mass of crystalline cellulose, 50 parts by mass of lactose, 4 parts by mass of magnesium stearate, and the remainder of cornstarch are mixed. and tableting to prepare the liver function improving agent of the present invention in the form of a tablet.
（配合例８：顆粒剤）
全体を１００質量部として、テクトリゲニン類粉末 ５質量部、黒ショウガ抽出物 １５質量部、乳糖 １０質量部、ステアリン酸カルシウム １質量部及び結晶セルロース 残部を混合及び顆粒化することにより、顆粒剤の態様で本発明の肝機能改善剤を調製した。
(Formulation example 8: Granules)
By mixing and granulating 5 parts by mass of tectorigenin powder, 15 parts by mass of black ginger extract, 10 parts by mass of lactose, 1 part by mass of calcium stearate, and the remainder of crystalline cellulose, the total amount is 100 parts by mass. A liver function improving agent of the present invention was prepared.
（配合例９：カプセル剤）
全体を１００質量部として、テクトリゲニン類抽出物 ２．５質量部、穀物麹 ２０質量部、レシチン ８質量部及びオリーブ油 残部を混合して調製したものを内容液として、これをカプセル殻に内包することにより、カプセル剤の態様で本発明の肝機能改善剤を調製した。
(Formulation Example 9: Capsule)
A total of 100 parts by mass is prepared by mixing 2.5 parts by mass of tectorigenin extract, 20 parts by mass of grain koji, 8 parts by mass of lecithin, and the remainder of olive oil, and the content liquid is prepared and encapsulated in the capsule shell. The liver function improving agent of the present invention was prepared in the form of a capsule.
（配合例１０：液剤）
全体を１００質量部として、テクトリゲニン類粉末 ０．３３質量部、Ｌ－アラニン ０．１質量部、果糖ブドウ糖液糖 １０質量部、クエン酸 １質量部、安息香酸ナトリウム ０．０２質量部、香料 ２質量部、スクラロース ０．０５質量部、アセスルファムカリウム ０．０３質量部及び精製水 残部を混合して、液剤の態様で本発明の肝機能改善剤を調製した。
(Formulation Example 10: Liquid)
Taking the total as 100 parts by mass, 0.33 parts by mass of tectrigenin powder, 0.1 parts by mass of L-alanine, 10 parts by mass of fructose glucose liquid sugar, 1 part by mass of citric acid, 0.02 parts by mass of sodium benzoate, 2 parts by mass of fragrance Part by mass, 0.05 part by mass of sucralose, 0.03 part by mass of acesulfame potassium, and the remainder of purified water were mixed to prepare the liver function improving agent of the present invention in the form of a liquid preparation.
Claims (1)
（ａ）クロロゲン酸、クルクミン、カフェインから選ばれる少なくとも１種の機能性添加剤
（ｂ）アスパルテーム、麦芽糖、フラクトオリゴ糖から選ばれる少なくとも１種の甘味料
（ｃ）ヨモギ、米ぬか、米胚芽から選ばれる少なくとも１種の植物素材
（ｄ）穀物麹、黒酢、小麦ふすま発酵エキス末、もろみ酢、ビール酵母から選ばれる少なくとも１種の発酵関連素材 An oral composition characterized by containing at least one component selected from tectorigenin, tectorizin, and tectorigenin 7-O-xylosylglucoside, and at least one component selected from the group consisting of (a) to (d) below. thing.
(a) At least one functional additive selected from chlorogenic acid, curcumin, and caffeine (b) At least one sweetener selected from aspartame, maltose, and fructooligosaccharide (c) Selected from mugwort, rice bran, and rice germ (d) At least one fermentation-related material selected from grain koji, black vinegar, fermented wheat bran extract powder, moromi vinegar, and beer yeast.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023210781A JP2024023667A (en) | 2016-03-16 | 2023-12-14 | Liver function improver |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016052940A JP6718158B2 (en) | 2016-03-16 | 2016-03-16 | Liver function improver |
| JP2020093592A JP7320270B2 (en) | 2016-03-16 | 2020-05-28 | Liver function improver |
| JP2022069053A JP2022089939A (en) | 2016-03-16 | 2022-04-19 | Liver function improver |
| JP2023210781A JP2024023667A (en) | 2016-03-16 | 2023-12-14 | Liver function improver |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069053A Division JP2022089939A (en) | 2016-03-16 | 2022-04-19 | Liver function improver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2024023667A true JP2024023667A (en) | 2024-02-21 |
Family
ID=87469816
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020093592A Active JP7320270B2 (en) | 2016-03-16 | 2020-05-28 | Liver function improver |
| JP2022069053A Pending JP2022089939A (en) | 2016-03-16 | 2022-04-19 | Liver function improver |
| JP2023210781A Pending JP2024023667A (en) | 2016-03-16 | 2023-12-14 | Liver function improver |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020093592A Active JP7320270B2 (en) | 2016-03-16 | 2020-05-28 | Liver function improver |
| JP2022069053A Pending JP2022089939A (en) | 2016-03-16 | 2022-04-19 | Liver function improver |
Country Status (1)
| Country | Link |
|---|---|
| JP (3) | JP7320270B2 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2574185A1 (en) | 2004-07-26 | 2006-02-02 | Toyo Shinyaku Co., Ltd. | Body fat-reducing agent |
| JP5052011B2 (en) | 2005-02-10 | 2012-10-17 | 株式会社東洋新薬 | Blood flow improver |
| JP2006265236A (en) * | 2005-02-28 | 2006-10-05 | Toyo Shinyaku:Kk | Hepatocyte activator |
| JP4997488B2 (en) * | 2007-03-30 | 2012-08-08 | 株式会社ジェイテクト | Compound gear and electric power steering device |
| CN102648751B (en) * | 2012-05-02 | 2013-10-23 | 中国食品发酵工业研究院 | Engineering rice with functions of alleviating hangover and protecting liver and preparation method of engineering rice |
| JP5569848B2 (en) * | 2012-09-13 | 2014-08-13 | 株式会社東洋新薬 | Composition containing black ginger ingredients |
| JP2015027998A (en) * | 2013-06-24 | 2015-02-12 | 株式会社東洋新薬 | Moisturizer, skin barrier function activator, tight junction formation accelerator, trpv4 expression enhancer, intracellular calcium concentration increaser, intracellular calcium concentration increaser, lipid synthesis accelerator, blood flow improver and periocular darkness ameliorator |
-
2020
- 2020-05-28 JP JP2020093592A patent/JP7320270B2/en active Active
-
2022
- 2022-04-19 JP JP2022069053A patent/JP2022089939A/en active Pending
-
2023
- 2023-12-14 JP JP2023210781A patent/JP2024023667A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7320270B2 (en) | 2023-08-03 |
| JP2020125362A (en) | 2020-08-20 |
| JP2022089939A (en) | 2022-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6745250B2 (en) | Moringa extract | |
| JP6682073B2 (en) | Liver function improver | |
| JP6714928B2 (en) | Collagenase inhibitor | |
| JP7226843B2 (en) | Liver function improver | |
| JP2017141201A (en) | Glycosylation inhibitor | |
| JP2010265251A (en) | Bloodstream-promoting/improving agent | |
| JP7112786B2 (en) | Absorption enhancer for shogaol and/or gingerol | |
| JP2017141200A (en) | Absorption-promoting agent of shogaol and/or gingerol | |
| JP2010095529A (en) | Composition for improving lipid metabolism | |
| JP5027361B2 (en) | Hyaluronic acid production promoter | |
| JP6718158B2 (en) | Liver function improver | |
| JP2010265215A (en) | Methioninase inhibitor | |
| JP2014105210A (en) | Composition containing white tea extract having activity of inhibiting skin crease formation and ameliorating crease | |
| JP7539717B2 (en) | Shogaol and/or gingerol absorption enhancer | |
| JP7320270B2 (en) | Liver function improver | |
| JP2015182987A (en) | Antiinflammatory agent | |
| JP5832714B2 (en) | Tyrosinase activity inhibitor and melanin production inhibitor | |
| JP7296611B2 (en) | Nitric oxide production accelerator | |
| JP2016216373A (en) | Blood-flow improving agent | |
| JP5422137B2 (en) | Whitening agent, tyrosinase activity inhibitor, melanin production inhibitor, and skin external preparation for whitening | |
| JP2019112470A (en) | Blood flow improver | |
| JP2007112721A (en) | Melanogenesis inhibitory composition, and beverage and food containing the same | |
| JP6829487B2 (en) | Anti-fatigue | |
| JP7156720B2 (en) | glycation inhibitor | |
| JP6906248B2 (en) | Cosmetology composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231214 |